1. Home
  2. FAX vs CTMX Comparison

FAX vs CTMX Comparison

Compare FAX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FAX
  • CTMX
  • Stock Information
  • Founded
  • FAX 1986
  • CTMX 2008
  • Country
  • FAX United States
  • CTMX United States
  • Employees
  • FAX N/A
  • CTMX 121
  • Industry
  • FAX Investment Managers
  • CTMX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FAX Finance
  • CTMX Health Care
  • Exchange
  • FAX Nasdaq
  • CTMX Nasdaq
  • Market Cap
  • FAX 672.5M
  • CTMX 544.2M
  • IPO Year
  • FAX N/A
  • CTMX 2015
  • Fundamental
  • Price
  • FAX $15.79
  • CTMX $3.28
  • Analyst Decision
  • FAX
  • CTMX Strong Buy
  • Analyst Count
  • FAX 0
  • CTMX 5
  • Target Price
  • FAX N/A
  • CTMX $5.30
  • AVG Volume (30 Days)
  • FAX 833.6K
  • CTMX 4.4M
  • Earning Date
  • FAX 01-01-0001
  • CTMX 11-06-2025
  • Dividend Yield
  • FAX 12.09%
  • CTMX N/A
  • EPS Growth
  • FAX N/A
  • CTMX 263.20
  • EPS
  • FAX N/A
  • CTMX 0.49
  • Revenue
  • FAX N/A
  • CTMX $141,100,000.00
  • Revenue This Year
  • FAX N/A
  • CTMX N/A
  • Revenue Next Year
  • FAX N/A
  • CTMX N/A
  • P/E Ratio
  • FAX N/A
  • CTMX $6.69
  • Revenue Growth
  • FAX N/A
  • CTMX 18.01
  • 52 Week Low
  • FAX $2.33
  • CTMX $0.40
  • 52 Week High
  • FAX $2.84
  • CTMX $3.49
  • Technical
  • Relative Strength Index (RSI)
  • FAX 29.87
  • CTMX 76.04
  • Support Level
  • FAX $16.15
  • CTMX $3.11
  • Resistance Level
  • FAX $16.68
  • CTMX $3.49
  • Average True Range (ATR)
  • FAX 0.23
  • CTMX 0.24
  • MACD
  • FAX -0.09
  • CTMX 0.11
  • Stochastic Oscillator
  • FAX 7.50
  • CTMX 86.82

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: